-
Cellectis starts alemtuzumab revival with FDA orphan drug win in leukaemia
02 Aug 2024 15:43 GMT
… sclerosis (MS), respectively. Campath was withdrawn from markets in … the drug to support Cellectis’s clinical trials as …
By GlobalData
Cellectis chief medical officer Mark Frattini said: … Gene Therapy coverage on Pharmaceutical Technology is supported by …
-
Immunotherapy Opens a “New Era” in Treating T-Cell Malignancies
05 Sep 2024 12:18 GMT
… and several clinical trials have been performed evaluating … ’T EAT ME.”2
Treatments that target surface antigens … ®; Kyowa Kirin), alemtuzumab (Campath®; Millennium and ILEX), isatuximab … Johnson & Johnson Innovative Medicine), and lacutamab. The ADCs …
-
T-Cell Exhaustion in CLL: Allogeneic CAR T Trial Reaching Patients With Unmet Need
30 Apr 2024 03:51 GMT
… disrupt CD52 (Campath-1 antigen); prior to treatment with cema- … been involved in several clinical trials regarding CLL,” he said. … relapsed or refractory chronic lymphocytic leukemia (CLL) or small … large B-cell lymphoma. CRISPR Medicine News. February 7, 2023 …
-
Advances in Immunotherapy for the Treatment of Cutaneous T-Cell Lymphoma
06 Sep 2023 08:51 GMT
… treatments for CTCL (mainly monoclonal antibodies and antibody-drug … Genetech/Roche; Adaptive Biotechnologies; Precision Biosciences; Genmab; … research funding from ONO Pharmaceuticals. AP reports no … tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720 …
-
Carina Biotech Appoints Two New U.S. Based Biotechnology Executives to the Board of Directors
05 Jun 2023 12:00 GMT
… . Food and Drug Administration (FDA) approved CAR- … group focused on pharmaceutical and biotech industries. Previously, … management positions at Genzyme Corporation, including as … the treatment of hyperphosphatemia, and Campath for chronic lymphocytic leukemia. …
-
What is T-cell prolymphocytic leukemia?
23 Mar 2023 14:30 GMT
… the surface of leukemia cells.
Chromosome … . Therefore, doctors may delay treatment and monitor … Medications: For people with symptomatic T-PLL, drugs, including intravenous alemtuzumab (Campath … Clinical trials may involve testing new drugs, drug combinations …
-
Glyscend Therapeutics Appoints Biotech Industry Veteran Michael Wyzga to its Board of Directors
30 Mar 2023 12:33 GMT
… a clinical-stage biotechnology company pioneering a … Phase 1 trial, I believe this drug, with its … the treatment of hyperphosphatemia and Campath for chronic lymphocytic leukemia. … plc, OncoMed Pharmaceuticals, Inc., X4 Pharmaceuticals, GenSight Biologics, …
-
Biosimilar Lymphocyte Modulator Market Growth Analysis With Investment Opportunities For 2024-2033
07 Aug 2024 09:55 GMT
… personalized medicine, growing demand for minimally invasive procedures, and expanding biologic drug … Humira (adalimumab).
Segments:
1) By Drug: Campath-1H, Natalizumab Biosimilar, Efalizumab - … as an aid in the treatment for cancer and autoimmune diseases …
-
Biosimilar Lymphocyte Modulator Global Market Report 2022: Growing Popularity of Immunotherapy for Cancer Treatment Driving Sector
08 Nov 2022 12:26 GMT
… main types of drugs in biosimilar lymphocyte modulator are campath-1H, natalizumab … shortages cause delayed and compromised medical treatments and also results in limiting … .
Scope
Markets Covered:
1) By Drug: Campath-1H; Natalizumab Biosimilar; Efalizumab - …
-
Morphic Congratulates Timothy A. Springer, PhD as 2022 Albert Lasker Basic Medical Research Award Honoree
28 Sep 2022 16:00 GMT
… medicine. Tim’s work has led to numerous new treatments … to the founding of multiple biotechnology companies (LeukoSite , Scholar … therapeutics including Amevive®, Raptiva®, Campath®, Velcade®, and Entyvio®. … 057 phase 2 clinical trials, any expectations about …